Navigation Links
Palatin Announces Strategic Realignment of Operations
Date:9/24/2010

CRANBURY, N.J., Sept. 24 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the realignment of its workforce and operations to reflect a strategic reassessment of its research and development activities and corporate objectives. As a result, Palatin will focus resources and efforts on clinical trials of bremelanotide for male and female sexual dysfunction and PL-3994 for acute severe asthma. In implementing this plan, Palatin is reducing its workforce by approximately 50% and discontinuing research activities relating to the discovery of new compounds.

"After critically reviewing our current research and development operations and plans, as well as other business activities, we made the decision to reposition Palatin.  We believe prioritizing our clinical programs and focusing on advancing our clinical drug candidates can generate the most value for our stockholders," stated Dr. Carl Spana, Palatin's President and Chief Executive Officer.

Palatin also announced that it is implementing a one-for-ten reverse stock split of its common stock, effective with the opening of trading on September 27, 2010.

Palatin's Strategic Priorities

Sexual Dysfunction

Bremelanotide for erectile dysfunction (ED):  In the fourth quarter of calendar 2010 we intend to submit protocols to the U.S. Food and Drug Administration (FDA) for initiation of a Phase 2 clinical trial of subcutaneously administered bremelanotide, as either monotherapy or a combination therapy with a PDE-5 inhibitor such as sildenafil, for men with ED who are non-responsive or inadequately responsive to PDE-5 inhibitor therapies alone. Assuming concurrence of the FDA, and depending on financial resources, this Phase 2 clinical trial for men with ED could start as early as the first quarter of calendar 2011.

Bremel
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
2. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
3. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
5. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
6. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
7. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
8. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
9. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
10. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
11. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... owners drew up their lists of New Year,s resolutions for 2014, ... my furry companion." Nowadays there are pet salons, dog and cat ... the little canine or feline darlings along wherever mommy or daddy ... toys at the pet store. But anyone who has ever lived ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... Kinaxis ®, provider of RapidResponse ®, a cloud-based supply ... ( S&OP ) service, is proud to be a gold ... held at the Hilton San Diego Bayfront, January 30 – ... Kaszas , Director of Supply Chain at Amgen, as she ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... TIME: 8:30 a.m. Eastern Time HOST: Dr. Candace ... Kendle, Chairman and CEO, ... conference call and simultaneous webcast Oct. 31,at 8:30 a.m. Eastern Time to ... session will follow. (Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO ) Webcast Instructions ...
... Texas, Oct. 10 Luminex Corporation,(Nasdaq: LMNX ) ... on Wednesday, October 24, 2007. Results are scheduled for ... a conference call to discuss the operating,highlights and financial ... October 25, 2007, at 8:00 a.m. Eastern time. ...
... Campbell Alliance, the leading,management consulting firm specializing in ... was recognized as one of the best,places to work ... by the,Triangle Business Journal, ranking third among midsize companies. ... Business Journal,s annual Best,Places to Work luncheon and awards ...
Cached Biology Technology:Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast 2Luminex Corporation Third Quarter Earnings Release Scheduled for October 24, 2007 2Luminex Corporation Third Quarter Earnings Release Scheduled for October 24, 2007 3Campbell Alliance Named 'Best Place to Work' by Triangle Business Journal 2
(Date:4/16/2014)... have identified a new syndrome called "osteosarcopenic obesity" that ... with obesity. , "It used to be the thinking ... would be because the bones were supporting more weight," ... at Florida State. "But, that,s only true to a ...
(Date:4/16/2014)... Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has just received ... in the amount of nearly US$600,000. The 5-year grant is ... called RNases and to explore their biomedical potential in the ... , "Receiving a grant at this level is ...
(Date:4/16/2014)... a densely packed array of finger-like projections called ... line our intestines., Vanderbilt University researchers have now discovered ... critical for absorbing nutrients and defending against pathogens. The ... , reveal a role for adhesion molecules in brush ...
Breaking Biology News(10 mins):Researchers: Obesity can amplify bone and muscle loss 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 2Vanderbilt researchers discover how intestinal cells build nutrient-absorbing surface 3
... rodents known as Murinae (mice, rats, etc.), which first ... the entire Old World (Eurasia, Africa, Australia) in less ... have long suspected that one of the reasons for ... apparatus. Now, researchers have used the brilliant X-ray beams ...
... beginning of October. The goal is to develop the production ... manufacture tires made from dandelion rubber. This is why molecular ... supplier built a pilot facility in Mnster that is capable ... time, they cultivate several hectares of a dandelion variety which ...
... bus, escaping a burning building or taking part in ... up knee problems for later in life, according to ... Journal of Biomedical Engineering and Technology . 9 ... fatigue, numbness and bunions when wearing such footwear. Despite ...
Cached Biology News:Chewing their way to success 2Fraunhofer and Continental come together when the dandelion rubber meets the road 2Fraunhofer and Continental come together when the dandelion rubber meets the road 3No running for the well-heeled 2
... a high quality whole genome sequencing service. ... costs allow even the smallest of laboratories ... key features which set our whole genome ... construction strategies, proprietary assembly software, rapid project ...
Great for biotinylating DNA/RNA probes...
... polyclonal antibody to human XAB2 (amino terminus) ... identified through its interaction with XPA. Immunoprecipitation ... of XAB2 interacts with the transcription-coupled repair-specific ... with RNA polymerase II. Microinjection experiments with ...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
Biology Products: